Phibro Animal Health (NASDAQ:PAHC) Hits New 1-Year High - Should You Buy?

Key Points

• Phibro Animal Health hit a new 52-week high, trading as high as $58.84 (last $58.17) during the session with shares up roughly 4.9%.
• The company beat quarterly estimates—EPS $0.87 vs. $0.69 expected and revenue $373.91M vs. $355.64M—and provided FY2026 guidance of 2.93–3.10 EPS.
• Insiders have been net sellers (316,472 shares worth about $15.3M in the past three months, including CEO sales), even as insiders are reported to own 50.13% of the stock and institutional investors about 99.34%.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $58.84 and last traded at $58.1680, with a volume of 329 shares. The stock had previously closed at $55.66.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PAHC. Weiss Ratings restated a "buy (b-)" rating on shares of Phibro Animal Health in a report on Monday, December 29th. Zacks Research upgraded shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 11th. Finally, Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.50.

Phibro Animal Health Stock Up 4.9%

The business's fifty day moving average is $51.09 and its two-hundred day moving average is $44.10. The company has a market cap of $2.37 billion, a P/E ratio of 26.06, a price-to-earnings-growth ratio of 0.85 and a beta of 0.69. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The company had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th were issued a dividend of $0.12 per share. The ex-dividend date was Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a yield of 0.8%. Phibro Animal Health's dividend payout ratio (DPR) is presently 21.33%.

Insiders Place Their Bets

In other news, CEO Jack Bendheim sold 7,040 shares of the business's stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $52.52, for a total value of $369,740.80. Following the completion of the sale, the chief executive officer owned 73,320 shares in the company, valued at approximately $3,850,766.40. The trade was a 8.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 316,472 shares of company stock worth $15,265,419. Company insiders own 50.13% of the company's stock.

Institutional Investors Weigh In On Phibro Animal Health

Large investors have recently modified their holdings of the business. Penserra Capital Management LLC bought a new stake in shares of Phibro Animal Health in the 3rd quarter valued at about $519,000. Capricorn Fund Managers Ltd bought a new stake in shares of Phibro Animal Health in the 3rd quarter valued at about $10,233,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Phibro Animal Health in the 3rd quarter valued at about $8,931,000. Citigroup Inc. raised its holdings in shares of Phibro Animal Health by 112.3% in the 3rd quarter. Citigroup Inc. now owns 54,941 shares of the company's stock valued at $2,223,000 after purchasing an additional 29,066 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Phibro Animal Health in the 2nd quarter valued at about $813,000. Institutional investors own 99.34% of the company's stock.

About Phibro Animal Health

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.